FDA approves implantable device to treat moderate to severe central sleep apnea

The U.S. Food and Drug Administration today approved a new treatment option for patients who have been diagnosed with moderate to severe central sleep apnea. The Remed ē System is an implantable device that stimulates a nerve located in the chest that is responsible for sending signals to the diaphragm to stimulate breathing.
Source: Food and Drug Administration - Category: American Health Source Type: news